Sintilimab plus IBI305 for hepatocellular carcinoma

Affiliations

¹ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. Electronic address: davidbomze@mail.tau.ac.il.
² Shamir Medical Center, Tzrifin, Israel.
³ Centre Hépato-Biliaire, Paul Brousse Hospital, Villejuif, France.

Comment

David Bomze et al. Lancet Oncol. 2021 Sep.

. 2021 Sep;22(9):e386.

doi: 10.1016/S1470-2045(21)00388-0.

¹ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. Electronic address: davidbomze@mail.tau.ac.il.
² Shamir Medical Center, Tzrifin, Israel.
³ Centre Hépato-Biliaire, Paul Brousse Hospital, Villejuif, France.

No abstract available

Conflict of interest statement

We declare no competing interests.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.